BackFreeline Therapeutics Holdings plc Overview

Freeline Therapeutics Holdings plc Current Cash

Track Freeline Therapeutics Holdings plc's current cash ($29M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$29.45M
55.27% YoYΔ $-36.40M vs prior year quarter

Peer average

Loading

Freeline Therapeutics Holdings plc Current Cash History

Loading

Freeline Therapeutics Holdings plc vs. peers: Current Cash Comparison

Loading

Freeline Therapeutics Holdings plc Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Freeline Therapeutics Holdings plc (FRLN) FAQ

Freeline Therapeutics Holdings plc (FRLN) currently reports a current cash of $29M as of September 2023. That compares with $66M in the prior-year period — down 55.3% year over year. Use the charts on this page to explore Freeline Therapeutics Holdings plc's current cash history and peer comparisons.

Freeline Therapeutics Holdings plc's current cash decreased from $66M to $29M — a 55.3% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Freeline Therapeutics Holdings plc reported $29M in current cash as of September 2023. That compares with $66M in the prior-year period — down 55.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $29M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Freeline Therapeutics Holdings plc, and consider following FRLN for alerts when major investors trade the stock.

Freeline Therapeutics Holdings plc is classified in the Healthcare sector. On current cash, it currently shows $29M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FRLN with unrelated industries.